Revvity, Inc. (RVTY)

FairStock Score: 31/100 — RISKY

Key Financials

Strengths

• Genuine free cash flow generation of $523.3M demonstrates operational substance and capital efficiency in cash conversion
• Market position in attractive high-growth sectors: diagnostics, life sciences, and genetic testing with durable competitive moats
• Latest quarter shows operational execution with 12.74% net margin and $772M revenue with reasonable leverage at 0.47 D/E
• Solid Piotroski F-Score of 7/9 indicates fundamentally sound accounting and financial trends
• 11,000 employees and established global distribution provide structural advantages

Concerns

• Grotesque valuation disconnect: P/E of 41.72 and EV/EBITDA of 58.29 with Graham Number at $35.76 representing -152% margin of safety
• Abysmal capital returns: ROE of 3.22% and ROCE of 2.22% indicate management is destroying shareholder value despite cash generation
• Altman Z-Score of 2.13 sits in gray zone; combined with minimal growth visibility, suggests heightened financial risk
• FCF yield of 1.6% is inadequate compensation for equity risk; capital allocation appears inefficient
• Missing growth data and declining stock momentum (from $119.02 to $90.30) suggest market confidence is eroding

AI Analysis

Revvity presents a classic case of a well-established business trading at an unjustifiable premium. The company operates in attractive end markets—diagnostics and life sciences—with reasonable competitive moats through its installed base and proprietary assay platforms. The latest quarter shows solid operational execution: $772M in revenue with a respectable 12.74% net margin and $523M in free cash flow. That's genuine cash generation, which I respect. However, the valuation is deeply problematic. At $90.30 per share with a P/E of 41.72 and an EV/EBITDA of 58.29, we're paying an extraordinary multiple for what appears to be a mature, single-digit growth business. The Graham Number of $35.76 suggests we're overpaying by 152%—a margin of safety that points backwards, not forwards. The ROE of 3.22% and ROCE of 2.22% are genuinely alarming for a company of this size; capital deployment is destroying value, not creating it. The Altman Z-Score of 2.13 sits in the gray zone, and despite a Piotroski score of 7/9 indicating decent financial health, the company isn't generating the returns shareholders deserve. The FCF yield of 1.6% is meager. This is a business I might consider owning at $35-40, where the margin of safety exists, but at current prices, it's a value trap masquerading as a quality compounder. I've seen many diagnostics companies follow this pattern: excellent market position, adequate profitability, but insufficient growth and returns to justify premium valuations. The market is paying for perfection; the business is delivering adequacy.

Bull Case

Revvity operates in secular growth markets (diagnostics, pandemic preparedness, genetic screening) with recurring revenue models and sticky customer relationships. The $523M in annual free cash flow could support meaningful shareholder returns if management improves capital discipline, potentially unlocking 8-12% annual returns if the company reinvests for modest 5-7% organic growth.

Bear Case

The 3.2% ROE on a $10.2B market cap reveals a business generating insufficient returns on deployed capital, and the 41x P/E ratio offers zero margin of safety for investors. If growth stalls or economic headwinds hit diagnostics demand, the stock could compress toward $50-60, erasing another 40% of shareholder value.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer